Skip to content

MapLight Therapeutics, Inc. MPLT Change in Lease Liabilities

Change in Lease Liabilities at other companies

LBR
LB Pharmaceuticals Inc Common StockLBRX
-$99K-5,050%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$349K-13.7%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$123K+35.3%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
-$106K-9.3%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
-$101K+66.7%
Maze Therapeutics, Inc. Common Stock logo
Maze Therapeutics, Inc. Common StockMAZE
-$915K-13.7%

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$1.39B+100%
Enterprise value$1.34B

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's change in lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's change in lease liabilities?
MapLight Therapeutics, Inc. (MPLT) reported change in lease liabilities of -$211K in Q1 2026.
What does change in lease liabilities mean?
Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.